Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Modified Boxplots00:57

Modified Boxplots

11.3K
A standard box and whisker plot informs us about the spread of the data in a given sample. One can identify the minimum value, maximum value, first quartile value, second quartile or median value, and third quartile.
However, the box plot does not tell the reader about outliers - values that lie far from the center of the data. We can modify the standard box and whisker plot to identify the outliers and visualize the actual spread of the data in a sample.
Initially, we calculate the adjusted...
11.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.9K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.9K
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

16
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
16
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

17
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
17
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

18
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
18

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Respiratory Viral Infections and the Tonsillar Transcriptome: An Exploratory Study.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

'What' and 'How' to Measure in Allergy and Clinical Immunology: A Systematic Review of Core Outcome Sets and Outcome Harmonisation Processes.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

The Role of B Cells and Antibodies in Eosinophilic Esophagitis.

Inflammatory intestinal diseases·2026
Same author

Effects of Common Food Additives Kappa-, Iota- and Lambda-Carrageenans on Intestinal Epithelial Cell Activation and Barrier Disruption.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Patterns and Clinical Efficacy of Biologics Switching in Patients With Severe Asthma: A Systematic Review and Meta-Analysis.

Allergy·2026

Related Experiment Video

Updated: Feb 14, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.0K

Modified Allergens for Immunotherapy.

Pattraporn Satitsuksanoa1, Anna Głobińska1,2, Kirstin Jansen1

  • 1Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270, Davos, Switzerland.

Current Allergy and Asthma Reports
|February 17, 2018
PubMed
Summary

Modified allergens offer improved efficacy and safety for allergen-specific immunotherapy (AIT). Research shows these modified allergens can induce immune tolerance, with promising clinical trial results for common allergens.

Keywords:
Allergen-specific immunotherapyAllergoidsCOPsHypoallergensNanoparticlesSPIREs

More Related Videos

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

3.1K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Related Experiment Videos

Last Updated: Feb 14, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.0K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

3.1K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Area of Science:

  • Immunology
  • Allergy Research
  • Biotechnology

Background:

  • Allergen-specific immunotherapy (AIT) aims to enhance treatment efficacy and reduce adverse effects.
  • Advances in recombinant DNA technology have spurred the development of modified allergens.

Purpose of the Study:

  • To review various types of modified allergens.
  • To discuss their mechanisms of action.
  • To explore their potential in improving AIT.

Main Methods:

  • Review of existing literature on modified allergens.
  • Analysis of different allergen modification strategies (peptides, allergoids, nanoparticles).
  • Examination of clinical trial data for modified allergens.

Main Results:

  • Modified allergens demonstrate reduced IgE reactivity while retaining T cell reactivity, facilitating immune tolerance.
  • Clinical trials show promising results for modified cat, grass, birch pollen, and house dust mite allergens.
  • These modifications enhance AIT safety and long-term efficacy.

Conclusions:

  • Modified allergens represent a promising advancement in AIT.
  • Further large-scale clinical studies are needed to confirm their added patient benefit.
  • These innovations hold potential for improved allergy treatment outcomes.